The CASZ1 Knockout Raji Polyclonal Cells provide a CRISPR/Cas9-mediated gene disruption model in Raji B lymphocytes, generating a polyclonal population with targeted loss of CASZ1 function. This product is designed as a versatile loss-of-function tool for investigating the transcriptional regulatory roles of the zinc finger transcription factor CASZ1 in a B-cell lymphoma context. The polyclonal nature ensures representation of diverse editing outcomes while maintaining population-level consistency for robust experimental comparisons.
Raji cells are an EBV-positive Burkitt lymphoma B cell line derived from a patient with Burkitt lymphoma. These B lymphocytes retain features of humoral immunity, including antigen presentation and immunoglobulin secretion, and are widely utilized in immunology and cancer research. The EBV-transformed background provides a relevant model system for studying lymphomagenesis, Epstein-Barr virus interactions, and B-cell signaling pathways.
CASZ1 functions as a transcriptional repressor by recruiting the nucleosome remodeling and deacetylase (NuRD) complex to target gene promoters, leading to histone deacetylation and chromatin condensation. Key interacting partners include CHD4, HDAC1, HDAC2, MTA2, and MBD3. CASZ1 is regulated by upstream factors such as E2F1, NOTCH1, TBX5, and NKX2-5, and it transcriptionally represses downstream targets including CDKN1A (p21), MYCN, and TAGLN. Consequently, CASZ1 integrates signals from developmental and oncogenic pathways, including TGF-?? and NOTCH cascades, to control cellular proliferation and differentiation.
In the Raji B-cell lymphoma background, disruption of CASZ1 is expected to alleviate repression of proliferation-associated genes such as MYCN and CDKN1A, potentially altering cell cycle progression and apoptotic sensitivity. The loss of NuRD-mediated transcriptional silencing may further impact the epigenetic landscape and response to extrinsic signals. This knockout model thus provides a platform to dissect CASZ1-dependent regulatory networks in B-cell malignancies, where its tumor-suppressive roles may counteract lymphomagenesis.
Typical research applications include functional genomics of CASZ1 in B-cell lymphomas, mechanistic studies of NuRD-mediated epigenetic regulation, drug sensitivity screening for hematologic malignancies, and CRISPR-based synergy experiments. Researchers can employ validated assays such as Western blotting and RT-qPCR for target validation, RNA-seq for transcriptome-wide analysis, ChIP-qPCR for CASZ1 binding site identification, immunofluorescence for NuRD localization, and functional assays including Annexin V/PI apoptosis assays, MTT proliferation assays, and chemotherapeutic drug sensitivity testing. For additional details and ordering information, please contact Ascent Research.
